63期专家简介

advertisement
Principal investigator/Program Director: Wu, Jian-MD, PhD
BIOGRAPHICAL SKETCH
Provide the following information for the key personnel in the order listed for Form Page 2.
Follow the sample format for each person. DO NOT EXCEED FOUR PAGES.
NAME
POSITION TITLE
Jian Wu (吴 健) 医学博士
Professor of Medicine
(医学教授)
EDUCATION/TRAINING (Begin with baccalaureate or other initial professional education, such as nursing, and include postdoctoral training.)
INSTITUTION AND LOCATION
DEGREE
(if applicable)
Nantong University Medical College (南通大学医
学院医学系), Nantong, Jiangsu, China
Southeast Univ. Medical College (东南大学医学
院), Nanjing, China
Bachelor D.
(医学学士)
Master D.
(医学硕士)
University of Umeå, Umeå, Sweden
医学博士
(Ph.D.)
(瑞典乌默尔大学医学院)
YEAR(s)
FIELD OF STUDY
1983 Clinical Medicine
1986 Internal Medicine/
Gastroenterology &
Hepatology
1994 Cell Biology, Medicine
and Clinical Chemistry
Business Address
复旦大学上海医学院
病原生物学系、医学分子病毒学教育部/卫生部重点实验室 228 信箱,中国上海市徐汇区医学院路 138
号。邮编:200032。电话:021-5423-7705(办公室)。电子邮件:[email protected]
Professional Experience
July 1986-Dec. 1988:
Teaching and Research Assistant and Resident Physician (助教/住院医生) in
Department of Internal Medicine, Southeast University Medical College (东南大学
医学院内科), Nanjing 210009, P. R. China;
Dec. 1988-Aug. 1990:
Lecturer and Consulting Physician ( 讲 师 / 主 治 医 生 ) in Division of
Gastroenterology and Hepatology, Dept. of Internal Medicine, Affiliated Hospital of
Southeast University Medical College ( 东 南 大 学 医 学 院 中 大 医 院 消 化 内 科 ),
Nanjing 210009, P. R. China;
Aug. 1990-Dec. 1994:
Research Fellow and Teaching Assistant in Department of Histology and Cell
Biology, University of Umeå, S-901 87 Umeå, Sweden;
Jan. 1995-May 1995:
Assistant Professor in Department of Internal Medicine, Section for
Gastroenterology and Hepatology, the Faculty of Medicine, University of Umeå, S901 87 Umeå, Sweden;
June 1995-Nov. 1997:
Post-Doctoral Research Fellow in Department of Medicine, Division of
Gastroenterology & Hepatology, Jefferson Medical College, Thomas Jefferson
University, Philadelphia, PA 19107-5083;
Dec. 1997-Sept. 1999:
Post-Doctoral Senior Scientist (NIH supported) in Department of Medicine,
Division of Gastroenterology & Hepatology, Jefferson Medical College, Thomas
Jefferson University, Philadelphia, PA 19107-5083;
Oct. 1999-June 2005
Assistant Professor (助理教授) in the Department of Internal Medicine, Transplant
Research Program, UC Davis Medical Center, Sacramento, CA 95817.
February 2004
Visiting Professor (访问教授), Fudan University Zhongshan Hospital, Shanghai, P.
R. China (上海复旦大学中山医院)
2003-Dec. 2014
Graduate Group of Comparative Pathology (Major Professor for PhD education)
(比较病理学博士生导师), UC Davis Graduate Studies. Davis, CA 95616, USA
Dec. 2004 to 6/2006
Coordination officer for Clinical Grant Proposals, Clinical Research Investigator
Support Program (CRISP), UC Davis School of Medicine, Sacramento, CA 95817
July 2005 to June 2009 Associate Professor (副教授), Level III, the Department of Internal Medicine,
Transplant Research Program, UC Davis Medical Center, Sacramento, CA 95817,
USA
2011 to 2012
Principal Investigator/Program Director (Last, first, middle):
委员会主席 of Professional Career Development of Academic Federation, UC Dais,
CA 95817, USA.
July 2009 to Dec.2014 Professor of Medicine (正教授). Department of Internal Medicine, Division of
Gastroenterology & Hepatology, UC Davis Medical Center, Sacramento, CA 95817.
2009 to Dec.2014
PI 资 格 : UC Davis Comprehensive Cancer Center, UC Davis Institute of
Regenerative Cures, Sacramento, CA 95817, USA .
Nov. 2011 to March 2013 复旦大学附属华山医院消化并研究所“千人计划”特聘教授
April 2013 至目前
复旦大学基础医学院病原生物学系/(教育部、卫生部)医学分子病毒学重点实
验室
2014 年至目前
复旦大学上海医学院-PerkinElmer 公司小动物活体影像示范实验室执行主任
2014 年至目前
复旦大学附属中山医院上海市肝病研究所脂肪肝、代谢性疾病研究中心主任。
国家及政府部门科研基金评审经历(National and Governmental Grant Reviewer Experience):
2004 to Present
中国香港特区政府香港卫生、福利、食品管理局终审评委 (The Health, Welfare
and Food Bureau, the Government of Hong Kong Special Administration Region,
The People’s Republic of China.
2005 to Present
香港特区政府研究资助局大学研究资助委员会终审评委 (University Grants
Committee, Research Grants Council of Hong Kong, P. R. China).
2005 to present
荷兰STW技术基金会外部评审专家(Technology Foundation STW of The
Netherlands)
2011 to present
美国纽约州公共卫生局和帝国州干细胞研究委员会课题终审专家(New York
Stem Cell Grant Reviewer invited by New York State Department of Health and the
Empire State Stem Cell Board NYSTEM Program, USA).
2011 to present
罗马尼亚国家发展与创新委员会联合学术委员会课题评审专家(The Romanian
National Council for Development and Innovation (RNCDI) for the evaluation of
Partnership Programme – Joint Applied Research Projects - PCCA 2011).
2012 to present
葡萄牙科学技术基金委员会(FCT)专家评审。
2012 to present
法国公共科学组织(CNRS) 法国国立卫生医学科学院( INSERM)专家评审
2012 to present
中国自然科学基金评审专家
2014 to present
英国皇家研究委员会(United Kingdom Research Council RCUK)评审专家
生物医药公司咨询:
2003 年 3 月
咨询专家组成员: Genteric Xerostomia expert's meeting. Genteric Corporation,
Alameda, CA.
2008 年 8 月
咨询专家:Tacere Therapeutics, 美国加州圣何赛市。
2010 年 6 月-2012 年 7 月 咨询专家: Genzen Personal Medicine & Discovery LLC, 美国加州戴维斯。
2005 至现在
咨询专家:Gerson Lehrman Group, 美国纽约州纽约市。
2010 年 8 月
咨询专家访问:Nitto Denko Technical Corp,美国加州海洋边市(Oceanside city,
CA)。
External Editorial Consultant:
03/2001 to Present
Managing editor: Frontiers in Bioscience.
07/2002 to Present
External consultant: Journal of Pharmacology and Experimental Therapeutics,
Molecular Therapy, Biochemical Pharmacology, Biochimica et Biophysica
Acta, Journal of Control Release.
01/2003 to present
Gene Therapy, Biochemical Pharmacology, Journal of Hepatology, Hepatology.
2005 to present
External Consultant: Biotechnology and Applied Biochemistry, International
Journal of Pharmaceutics, Journal of Biology Chemistry, American Journal of
Physiology, Laboratory Investigation, Liver International, Digestive Disease
Science, Molecular Medicine, Life Science, Transplantation, Plos One, America
Journal of Transplantation, Cancer Letters, AntiCancer Research, etc.
2004-Present
Editorial Board members and copy editor: Would Journal of
Gastroenterology, Beijing, P. R. China.
2009 to present
Review Editor: Stem Cells (IF: 7.871), Antioxidants & Redox Signaling (IF:
7.581), Gastroenterology & Hepatology Research. 临床肝胆病杂志编委
HONORS AND AWARDS:
1.
Glaxo gastoenterology scholarship 91-93, Gothenburg, Sweden.
PHS 398/2590 (Rev. 05/01)
2
Page _______
Biographical Sketch Format Page
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
Principal Investigator/Program Director (Last, first, middle):
Ph. D. student scholarship, University of Umeå, Umeå, Sweden, 08/90-12/94.
Research Award from the Swedish Doctors' Society, 1995.
Fellowship Award from the Swedish Association of Medical Research (Svenska Sällskapet för
Medicinsk Forskning, SSMF), 1997 (National level).
National Service Research Award (NSRA) from the National Institutes of Health, the National
Institute of Diabetes, Digestive and Kidney Diseases (NIDDK), 1997 (national level).
Liver Scholar Award by the American Liver Foundation & the American Association for the Study
of Liver Diseases (AASLD) 2000 (National level)
Travel Award by American Association for the Study of Liver Disease (AASLD), 2000
UC Davis Health System Award by UC Davis Health System, 2000
Short Term Research Award for Selected Outstanding Oversea Chinese Scholars by Chinese Academy
of Science, P. R. China, 2001
Research Award from Transplant Hope, UC Davis Medical Center, Sacramento, CA 2002
Research Award from the American Cancer Society, 2003-2004 (National level)
Exploratory Research Award (R21) by the National Institute of Diabetes, Digestive and Kidney
Diseases (NIDDK). 2004-2007 (National level).
Innovative Development Award by Academic Federation, UC Davis. 2006-2008.
Technology Transfer Grant Award, UC Davis Medical Center, Sacramento, CA 2007
Shanghai Thousand Talented Expert award (上海千人计划专家奖), Shanghai, China, 2011.
南京创业人才 321 计划奖, 南京 2012
Professional Societies:
1999-present
Permanent membership of the Frontiers in Bioscience Society of Scientists
2001-Present
Member: the American Association for the Study of Liver Diseases (AASLD)
2001-Present
Member: the American Society of Gene Therapy (ASGT).
2005 to present
Member: International Society for Stem Cell Research (ISSCR)
2010 to present
Member: American Association for the Advance of Science (AAAS)
PUBLICATIONS (selected from 110 peer-reviewed original papers, reviews and book chapters)
1.
Jiang Z, You DY, Chen XC and Wu J. Monitoring of serum markers of fibrosis during CCl4-induced
liver damage. Effects of anti-fibrotic agents. J Hepatol 1992; 16:282-289 (senior author). impact factor:
9.34
2.
Wu J, Lindström P, Danielsson Å, Sehlin J. Insulin secretion in pancreatic islets from rats with cirrhosis.
J Hepatol 1994; 21: 332-339 (senior author). impact factor: 9.34
3.
Jin TY, Nordberg GF, Sehlin J, Leffler P, Wu J. Augmented susceptibility of spontaneously diabetic
mice to nephrotoxicity induced by cadmium-metallothionein. Toxicology 1994; 89: 81-90.
4.
Wu J, Danielsson Å, Lindström P, Karlsson K, Sehlin J. The protective effects of calcium channel
blockers on bromobenzene-induced damage to isolated rat hepatocytes. inhibition of phenylephrine
stimulated calcium oscillations. Scand J Gastroenterol 1995; 30: 590-600 (senior author).
5.
Wu J, Söderbergh H, Karlsson K, Danielsson Å. Protective effect of S-adenosyl-L-methionine on
bromobenzene- or D-galactosamine toxicity to isolated rat hepatocytes. Hepatology 1996; 23: 359-365.
Impact factor: 11.67
6.
Wu J, Karlsson K, Danielsson Å. Protective effect of Trolox C, vitamin C and catalase on
bromobenzene-induced damage to rat hepatocytes. Scand J Gastroenterol 1996; 31: 797-803.
7.
Wu J, Norton PA. Animal models of liver fibrosis. Scand J Gastroenterol 1996; 31:1137-1143.
8.
Wu J. Zern MA. Modification of liposomes for liver targeting. J Hepatol 1996; 24:757-763. Impact factor:
9.34
9.
Wu J, Karlsson K, Danielsson Å. Effects of vitamin E, ascorbic acid and catalase on bromobenzene- and
hydrogen peroxide-induced intracellular oxidation and single strand DNA breakage in Hep G2 cells. J
Hepatol 1997; 26: 669-677. impact factor: 9.34
10.
Wu J, Kuncio GS, Zern MA. Human liver growth in fibrosis and cirrhosis. In Strain AJ, Diehl AM, Eds.
Liver Growth and Repair. Chapman & Hall, London. 1998: 558-576.
11.
Wu J, Liu P, Zhu JL, Maddukuri S, Zern MA. Increased liver up-take of liposomes and improved
targeting efficacy by labeling with asialofetuin in rodents. Hepatology 1998; 27: 772-778. Impact
factor: 11.67
12.
Zhu JL, Wu J, Frizell E, Liu SL, Bashey R, Rubin R, Norton PA. Zern MA. Rapamycin inhibits hepatic
stellate cell proliferation in vitro and limits fibrogenesis in an in vivo model of liver fibrosis.
Gastroenterology 1999; 117:1198-1204. Impact factor: 12.455
PHS 398/2590 (Rev. 05/01)
3
Page _______
Biographical Sketch Format Page
13.
14.
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
31.
32.
33.
34.
35.
36.
37.
Principal Investigator/Program Director (Last, first, middle):
Wu J, Wu GY, Zern MA. The prospects of hepatic drug delivery and gene therapy. Exp Opin Invest
Drugs 1998; 7: 1795-1817 (senior author).
Di Campli C, Wu J, Zern MA. Gene therapy for human liver disease. Eur J Gastroenterol Hepatol
1999; 11: 421-429.
Wu J, Danielsson Å, Zern MA. Toxicity of hepatotoxins: new insights into mechanisms and therapy.
Exp Opin Invest Drugs 1999; 8: 585-607 (senior author).
DiCampli C, Wu J, Zern M.A. Liver targeting approaches for fibrosis. Alcoholism: Clin Exp Res 1999;
23: 950-954.
Wu J, Danielsson Å, Zern MA. Use of isolated hepatocytes in study of xenobiotic hepatotoxicity. In
Berry MN & Edwards AM, Eds. Hepatocyte Review, Kluwer Academic Publishers, Dordercht, The
Netherlands. 2000: 455-474 (senior author).
Wu J, Liu SL, Zhu JL, Norton PA, Nojiri S, Hoek JB, Zern MA. Tissue transglutaminase (tTG)
functions as a G protein and as a cross-linking molecule in ethanol-induced inhibition of hepatocyte
proliferation. J Biol Chem 2000; 275:22213-22219.
Wu J, Zern MA. Hepatic stellate cells: a target for the treatment of liver fibrosis. J Gastroenterol 2000;
35: 665-672 (senior author).
Di Campli C, Nocente R, Costamagna G, Gentiloni N, Burioni R, Wu J, Armuzz A, Zern MA,
Gasbarrini G, Gasbarrini A. No evidence of Helicobacter pylori sequences in pancreatic juices of
patients affected by chronic pancreatitis. Int J Pancreatol 2000; 28:181-185.
Wege H, Wu J, Zern MA. Novel therapeutic modalities for hepatic disease. In: Kiwmu Okita Eds,
Frontiers in Hepatology /Liver Cirrhosis. Springer-Verlag Tokyo, Tokyo. 2001:17-29.
Wu J, Lizarzaburu ME, Kurth MJ, Liu L, Wege H, Zern MA, Nantz MH. Cationic lipid polymerization
as a novel approach for constructing new DNA delivery agents. Bioconjugate Chem 2001; 12: 251-257
Wege H, Wu J, Santos, RM, Zern MA. Hepatocyte-based therapies for liver diseases: novel strategies
and updates. J Port Gastroenterol 2001; 8: 134-142.
Wu J, Nantz MH, Zern MA. Targeting hepatocytes for drug and gene delivery---emerging novel
approaches and applications. Front Biosci 2002; 7:d717-725 (senior author).
Liu L, Zern MA, Lizarzburu ME, Nantz MH, Wu J. Poly(cationic lipid)-mediated in vivo gene delivery
to mouse liver. Gene Therapy 2003; 10: 180-187 (senior author).
Wege H, Le HT, Chui MS, Liu L, Wu J, Giri R, Malhi H, Sappal BS, Kumaran V, Gupta S, Zern MA.
Telomerase reconstution immortalizes human fetal hepatocytes without disrupting their differentiation
potential. Gastroenterology 2003; 124: 432-444. Impact factor: 12.455
Shirahashi H, Wu J, Yamamoto N, Wege H, Wager B, Okita K, Zern MA. Differentiation of human and
mouse embryonic stem cells along a hepatocyte lineage. Cell Transplant 2004; 13: 197-211.
Wu J, Zern MA. Tissue transglutaminase, a key enzyme involved in liver diseases. Hepatology
Research 2004; 29: 1-8
Wu J, Liu L, Yen YD, Catana CM, Michael H. Nantz, Zern MA. Liposome-mediated extracellular
superoxide dismutase gene delivery protects against acute liver injury in mice. Hepatology 2004; 40:
195-204 (senior author). Impact factor: 11.67
Duan Y-Y, Wu J, Zhu J-L, Liu S-L, Ozaki I, Strayer DS, Zern MA. Gene therapy for human alpha 1antitrypsin deficiency in an animal model using sv40-derived vectors. Gastroenterology 2004; 127:
1222-1232. Impact factor: 12.455
Wu J. Inhibition of hepatitis viral replication by siRNA. Exp Opin Biol Ther 2004; 4(10): 1649-1659.
Yen DR, Zern MA, Wu J. Molecular therapy for hepatic fibrosis (invited book chapter). In Frank
Columbus Edits: Focus on Chemotherapy Research, Nova Science Publishers, Inc. Hauppauge, NY.
2006:1-23 (senior author).
Zhan S-S, Jiang XS, Wu J, Halsted C, Zern MA, Torok NJ. Phagocytosis of apoptotic bodies by hepatic
stellate cells induces NADPH oxidase and it is associated with liver fibrosis in vivo. Hepatology 2006;
43: 435-443. Impact factor: 11.67
Prosser CC, Yen RD, Wu J. Molecular therapy for hepatic injury and fibrosis – where are we? (editorial)
World J Gastroenterol 2006, 12: 509-515 (senior author).
Zhang YH, Gu JF, Zhao LL, He LF, Qian WB, Wang JH, Wang YG, Qian QJ, Qian C, Wu J, Liu XY,
Complete elimination of colorectal tumor xenograft by combined MnSOD and TRAIL gene-virotherapy.
Cancer Research 2006; 66(8): 4291-4298 (co-senior author).
Yamamoto N, Wu J, Catana A, Cai H,Strom S, Novikoff PM, Zern MA. An optimal culture condition
maintains human hepatocyte phenotype after long term culture. Hepatol Res 2006; 35:169-177.
He SQ, Zhang YH, Venugopal SK, Dicus CW, Perez RV, Ramsamooj R, Nantz MH, Zern MA, Wu J.
Delivery of antioxidative enzyme genes protects against ischemia/reperfusion-induced liver injury in
PHS 398/2590 (Rev. 05/01)
4
Page _______
Biographical Sketch Format Page
Principal Investigator/Program Director (Last, first, middle):
38.
39.
40.
41.
42.
43.
44.
45.
46.
47.
48.
49.
50.
51.
52.
53.
54.
55.
56.
57.
58.
mice. Liver Transplant 2006; 12: 1869-1879 (senior author).
Du SL, Pan H, Wang J, Lu WY, Wu J, Wang JY. Cyclic RGD Peptide-labeled liposomes for targeting
drug therapy of hepatic fibrosis in rats. J Pharmacol Exp Ther 2007; 322: 560-568 (co-senior author).
Qian JM, Zhang H, Wu XF, Chen XP, Wu J. Improvement of recipient survival after small size graft
liver transplantation in rats with pre-ischemic manipulation or administering antisense against NF-B.
Transplant Int 2007; 20: 784-789 (senior author).
Kim JW, Zhang YH, Zern MA, Rossi JJ, Wu J. Short Hairpin RNA Causes the Methylation of
Transforming Growth Factor- Receptor II Promoter and Silencing of the Target Gene in Rat Hepatic
Stellate Cells. Biochem Biophys Res Commun 2007; 359: 292-297 (senior author).
Zhang YH, Venugopal SK, He SQ, Liu PG, Wu J, Zern MA. The role of novel protein kinase  and 
isoforms for ethanol-induced apoptosis in primary rat hepatocytes. Cell Signaling 2007; 19:2339-2350.
Venugopal SK, Wu J, Catana AM, Eisenbud L, He SQ, Duan YY, Bishop C, Follenzi A, Gupta S, Zern
MA. Lentivirus-mediated copper-zinc superoxide dismutase gene delivery protects the liver in mice
against oxidative stress. Liver Int 2007; 27: 1311-22 (co-senior author).
Choi MS, Catana AM, Wu J, Borowsky AD, Gambhir SS, Gupta S, Zern MA. Use of Bioluminescent
Imaging to trace the transplantation of immortalized human fetal hepatocytes into mice. Cell
Transplant 2008;17: 899-909.
Liu PG, He SQ, Zhang YH, Wu J. Protective effects of apocynin and allopurinol on ischemia
/reperfusion-induced liver injury in mice. World J Gastroenterol 2008; 14: 2832-2837 (senior author).
Ma XC, Duan YY, Catana AM, Jung JJ, Wu J, VandeVoort K, Zern MA. Differentiation of rhesus
monkey embryonic stem cells along hepatocyte lineage. Cloning & Stem Cells 2008; 10:485-94.
Kim JW, Wu J. RNAi, a Powerful Research Tool and Potential Molecular Therapy for Liver Diseases.
In Yamada K & Hayashi S Eds: Small Interfering RNA: New Research. ISBN: 978-1-60692-158-6.
Nova Science Publishers, Inc. Hauppauge, NY. 2009: 2009: 101-120 (senior author).
Wu J, Hecker JH, Chiamvimonvat N. Antioxidant gene transfer for ischemic diseases. Advanced Drug
Delivery Reviews. 2009; 61: 351-363 (senior author, impact factor: 13.58)
Nyunt T, Dicus CW, Yappert MC, Cui YY, Huser TR, Nantz MH, Wu J. Physico-Chemical
characterization of Poly(Cationic) Lipid and Polylipid Nanoparticles for Liver-Based Gene Delivery.
Bioconjugate Chemistry 2009; 20:2047-2054 (senior author).
Tatsukawa H, Fukaya Y, Frampton F, Martinez-Fuentes A, Suzuki K, Kuo K-F, Nagatsuma K,
Shimokado K, Okuno M, Wu J, Iismaa S, Matsuura T, Tsukamoto H, Zern MA, Graham R, Kojima S.
Role of Transglutaminase 2 in Liver Injury via Crosslinking and Silencing of Transcription Factor, Sp1.
Gastroenterology 2009; 136:1783-95 (Impact factor: 12.455).
Venugopal SK, Jiang J, Kim T-H, Li Y, Wang S-S, Torok NJ, Wu J, Zern MA. Liver fibrosis causes
down-regulation of miRNA-150 and miRNA-194 in hepatic stellate cells and their over-expression
causes decreased stellate cell activation. Am J Physiol 2010; 298: G101-G106.
Yoon S-J, Kim T-H, Natarajan A, Wang S-S, Choi MS, Wu J, Zern MA, Senthil K Venugopal. Acute
liver injury up-regulates microRNA-491_5p in mice, and its over-expression sensitizes Hep G2 cells for
TNF--induced apoptosis. Liver Int 2010; 30: 276-287.
Lingala S, Cui Y-Y, Chen X, Ruebner BH, Qian X-F, Zern MA, Wu J. Immunohistochemical staining
of cancer stem cell markers in hepatocellular carcinoma. Exp Mol Pathol 2010; 89:27-35 (senior
author) (PMID: 20511115). The most downloaded paper in the journal, and an image on the face page.
Schie IW, Wu J, Rutledge JC, Zern MA, Huser T. Label-free monitoring of lipid droplet formation in
living primary hepatocytes after treatment with lipoprotein lipolysis products. J Biophotonics 2011;
4(6):425-34.
Chen XL, Murad M, Cui Y-Y, Yao L-J, Venugopal SK, Dawson K, Wu J. miRNA Signatures in
Remaining Liver of 50% Partial Hepatectomy and Small Size Liver Graft in Rat Recipients.
Transplantation; 2011: 91:293-299 (senior author).
Zhou P, Lessa N, Estrada DC, Lingala S, Zern MA, Nolta JA, Wu J. Decellularized Liver Matrix as a
Carrier for Transplantation of Human Fetal and Primary Hepatocytes in Mice. Liver Transplant 2011:
17:418-427 (senior author).
Chen XL, Lingala S, Zern MA, Nolta JA, Wu J. Epithelial Mesenchymal Transition and Hedgehog
Signaling Activation are Associated with Chemoresistance and Enhanced Metastasis of PoorlyDifferentiated Hepatoma Cells. J Hepatol 2011; 55: 838-845 (senior author, impact factor: 9.34).
Ghaedi M, Soleimani M, Sheikhfatollahi M, Azadmanesh K, Lotfi AS, Wu J. Mesenchymal stem cells
as vehicles for targeted delivery of antiangiogenic protein to solid tumor. J Gene Med 2011:13: 171180 (Senior author).
Ghaedi M, Tuleuova N, Zern MA, Wu J, Revzin A. Bottom-Up Stimulation and Hepatic Differentiation
PHS 398/2590 (Rev. 05/01)
5
Page _______
Biographical Sketch Format Page
Principal Investigator/Program Director (Last, first, middle):
59.
60.
61.
62.
63.
64.
65.
66.
67.
68.
69.
70.
71.
72.
73.
74.
75.
76.
of Mesenchymal Stem Cells Cultured on HGF-Containing Surfaces. Biochem Biophys Res Commun.
2011; 407:295-300.
Ellis CL, Ma ZM, Mann SK, Li CS, Wu J, Knight TH, Yotter Y, Hayes TL, Maniar AH, Troia-Cancio
PV, Overman HA, Torok NJ, Albanese A, Rutledge JC, Shacklett BL, Miller CJ, Pollard RB, Asmuth
DM. Phylogenetic order-level of stool microbiota in HIV-infected subjects. J AIDS 2011; 57:363-370.
Li F, Song Z-J, Li QH, Wu J, Wang J-Y, Xie C, Tu CT, Wang J, Huang X-W, Lu W-Y. Molecular
Imaging of Hepatic Stellate Cell Activity by Visualization of Hepatic Integrin v3 Expression with
SPECT in Rat. Hepatology 2011; 54: 1020-1030. (co-senior author, impact factor: 11.67).
Cui Y-Y, Qian J-M, Yao A-H, Ma Z-Y, Qian X-F, Zha X-M, Zhao Y, Ding Q, Liu X-A, Zhao J, Wang
S, Wu J. SOD Mimetic Improves the Function, Growth and Survival of Small Size Graft Liver
Transplantation in Rats. Transplantation 2012; 94(7):687–694 (senior author).
Wu L-J, Pan Y-D, Pei X-Y, Chen H, Nguyen S, Kashyap A, Liu J, Wu J. Capturing circulation tumor
cells from hepatocellular carcinoma. Cancer Letters 2012; 326: 17-72 (senior author)
Fan YH, Wu J. Polylipid nanoparticle, a Novel Lipid-based Vector for Liver Gene Transfer. In Dr.
Francisco Martin Edits: Gene Therapy Tools and Potential Applications (ISBN 980-953-307-690-9),
Intechopen, Rijeka, Croatia. 2013: 91-107 (Senior author). http://dx.doi.org/10.5772/54270.
Wu J. Coumarin, an alternative candidate for the treatment of non-alcoholic steatohepatitis? An Invited
Commentary in Br J Nutrition 2013; doi:10.1017/S0007114512005806. PMID: 23340308.
Chang A, Nolta JA, Wu J. Mesenchymal Stem Cells as a Carrier for Targeting Anti-Tumor
Therapeutics. In Gerhard Gross & Thomas Haeupl Eds: STEM CELL-DEPENDENT-THERAPIES MESENCHYMAL STEM CELLS IN CHRONIC INFLAMMATORY DISORDERS. ISBN 978-311-024042-9 De Gruyter Publisher, Berlin, Germany. 2013; in press (Senior author).
Magner NL, Jung Y, Wu J, Nolta JA, Zern MA, Zhou P. Insulin and IGFs Enhance Hepatocyte
Differentiation from Human Embryonic Stem Cells via the PI3K/AKT Pathway. Stem Cells 2013;
31:2095-2103 (DOI: 10.1002/stem.1478) (impact factor: 7.9).
Schie IW, Nolte L, Pedersen TL, Smith Z, Wu J, Yahiatene I, Newman JW, Huser T. Direct Comparison
of Fatty Acid Ratios in Single Cellular Lipid Droplets as determined by Comparative Raman
Spectroscopy and Gas Chromatography. Analyst 2013; 138(21): 6662-6670. DOI: 10.1039/C3AN00970J.
Ding J, Wang H, Wu J. Immunotherapy for Hepatocellular Carcinoma, How far from Clinical
Application? A Commentary (in Chinese). Chin J Hepatol 2014: 22(5):393-396 (Senior author).
Adkins Y, Schie IW, Fedor D, Reddy A, Nguyen S, Zhou P, Darshan S. Kelley DS, Wu J. A novel
mouse model of nonalcoholic steatohepatitis with significant insulin resistance. Lab Invest 2013;
93:1313–1322 (corresponding author). DOI: 10.1038/labinvest.2013.123. One image in the cover page.
Wang JP, Wang D-L, Wang H-T, Wang Z-H, Wen Y, Sun C-H, Zhao Y-T, Wu J, Liu P. Tumor
Necrosis Factor-Alpha-Induced Reduction of Glomerular Filtration Rate in Rats with Fulminant Hepatic
Failure. Lab Invest 2014; 94: 740–751. DOI:10.1038/labinvest.2014.71. Co-corresponding author.
Liu X-J; Xue R-Y; Ji L-L; Zhang X-W; Wu J; Gu J-X; Zhou M-L, Chen S. Activation of farnesoid X
receptor (FXR) protects against fructose-induced liver steatosis via inflammatory inhibition and ADRP
reduction. Biochem Biophys Res Commun 2014450: 117-123. doi: 10.1016/j.bbrc.2014.05.072.
Tang W-Q, Xue R-Y, Weng W-X, Wu J, Fang F, Wang Y, Ji L-L, Hu T-T, Liu T-T, Huang X-W, Chen
S, Shen X-Z, Zhang S, Dong L. BIRC6 promotes hepatocellular carcinogenesis: interaction of BIRC6
with p53 facilitating p53 degradation. Int J Cancer 2015;136(6):E475-87. DOI: 10.1002/ijc.29194
(impact factor: 6.5). PMID: 25196217.
SHIN H-S, SARIN R., DIXIT N, CHAO CC, WU J, IVASHKIV LB, BOWMAN EP,
ADAMOPOULOS IE. Crosstalk among interleukin 23 and DNAX activating protein 12-dependent
pathways
promotes
osteoclastogenesis.
J
Immunol
2015;194(1):316-24.
DOI:
10.4049/jimmunol.1401013. PMID: 25452564 (impact factor: 5.362). One figure on the cover.
Ding J, Wu J. Epigenetic Regulation of hepatic Tumor-initiating Cells. Frontiers in Bioscience2015; 20:
946-963 (landmarks). PMID: 25961535. DOI No:10.2741/2842. (Corresponding author).
Wecksler AT, Hwang SH, Liu JJ, Inoue H, Morisseau C, Fu SH, Wu J, Weiss RH Hammoc BD.
Biological Evaluation of a Novel Sorafenib Analogue, t-CUPM. Cancer Chemother Pharmacol 2015;
75(1):161-171. DOI 10.1007/s00280-014-2626-2, PMID: 25413440.
Fan Y-H, Ding J, Nguyen S, Liu X-J, Xu G, H Zhou H-Y, Duan N-N, Yang S-M, Zern MA, Wu J.
Aberrant Hedgehog Signaling is Responsible for the Highly Invasive Behavior of a Subpopulation of
Hepatoma Cells. Oncogene 2015 ; in press, Impact factor: 8.56 Corresponding author. DOI:
PHS 398/2590 (Rev. 05/01)
6
Page _______
Biographical Sketch Format Page
Principal Investigator/Program Director (Last, first, middle):
10.1038/onc.2015.67.
77.
Chang A, Nolta JA, Wu J. Involvement of Mesenchymal Stem Cells in Cancer Progression and
Metastases. Current Cancer Drug Targets 2015; 15(2): 88-98. (Corresponding author). Impact factor:
3.582 (5-year average: 5.15). PMID: 25619387.DOI: 10.2174/1568009615666150126154151
78.
Asmuth DM, Pinchuk IV, Wu J, Vargas G, Chen X-L, Mann S, Albanese A, Ma Z-M, Saroufeem R,
Melcher GP, Cancio PT, Torok NJ, Miller CJ, Powell DW. Role of Intestinal Myofibroblasts in HIVAssociated Intestinal Collagen Deposition and Immune Reconstitution following Combination
Antiretroviral Therapy. AIDS AIDS 2015; 29 (8 ):877 –888. Published online 3/11/2015. DOI:
10.1097/QAD.0000000000000636. PMID: 25784439 (impact factor: 6.557).
79.
Adkins Y, Fedor DM, Mackey BE, Wu J, Kelley DS. Reversal of Conjugated Linoleic Acid-Induced
Nonalcoholic Steatohepatitis and Fibrosis By Supplementation of Docosahexaenoic Acid in Mice.
Journal of Nutrition 2015; accepted for publication. Co-corresponding author. Impact factor: 4.3
Patent:
1.
Extracellular superoxide dismutase gene delivery to prevent oxidative injury. UCD#2003-483
Internationally covered.
2.
Decellularized Liver Matrix for Transplantation of Stem Cells or Hepatocytes. UCD:2011: 060933-6400
Non-Prevision filing.
Books:
1.
Jian Wu. Pathogenesis of Hepatocellular Damage, Hepatic Fibrosis and Cirrhosis in the Rat. Prevention
of Liver Damage and Inhibition of Fibrogenesis. Ph. D. Thesis, University of Umeå, Sweden. New
Series No. 418, ISSN 0346-6612, ISBN 91-7174-968-31994.
2.
Wu J & Norton PA. Editors: Hepatic Fibrosis and Targeting therapy, a Special Issue of Frontiers in
Bioscience: 2002 (http://www.bioscience.org/current/special/wu1.htm).
3.
Pei Liu, Jian Wu and Yu-min Wang Guest Editors: Hepatic Encephalopathy, Special Issue of
Gastroenterology & Hepatology Practice.
4.
Jian Wu. Editor: Cytochrome P450 Enzymes: Biochemistry, Pharmacology, and Health
Implications. Nova Scientific Publisher, Inc. Hauppauge, NY 11788-3619, USA. 2014: 194 pages.
ISBN: 978-1-61942-209-4。
PHS 398/2590 (Rev. 05/01)
7
Page _______
Biographical Sketch Format Page
Download
Related flashcards
Microbiology

23 Cards

Preservatives

48 Cards

Preservatives

48 Cards

Protista

20 Cards

Create flashcards